# EDGAR Filing Document

**Accession Number:** 0001779479
**File Stem:** 0001193125-25-301155
**Filing Date:** 2025-11
**Character Count:** 6855
**Document Hash:** 7f61b0cf03f6c282904354c4b96aeb85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-301155.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001193125-25-301155

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251125

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Rolph Timothy
- **CENTRAL INDEX KEY:** 0001779479

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38944
- **FILM NUMBER:** 251532264

**MAIL ADDRESS:**
- **STREET 1:** C/O AKERO THERAPEUTICS, INC.
- **STREET 2:** 601 GATEWAY BOULEVARD, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akero Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001744659
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 601 GATEWAY BOULEVARD, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-487-6488

**MAIL ADDRESS:**
- **STREET 1:** 601 GATEWAY BOULEVARD, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Rolph Timothy<br><sub>(Last) (First) (Middle)</sub><br>601 GATEWAY BOULEVARD<br>SUITE 350<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Scientific Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Akero Therapeutics, Inc. [ AKRO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-25 |  | M |  | 3527 | A | $28.35 | 132998 | D |  |
| Common Stock | 2025-11-25 |  | M |  | 43064 | A | $6.364 | 176062 | D |  |
| Common Stock | 2025-11-25 |  | M |  | 4284 | A | $21.09 | 180346 | D |  |
| Common Stock | 2025-11-25 |  | M |  | 2796 | A | $0.615 | 183142 | D |  |
| Common Stock | 2025-11-25 |  | M |  | 94268 | A | $0.615 | 277410 | D |  |
| Common Stock | 2025-11-25 |  | M |  | 4739 | A | $21.1 | 282149 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $0.615 | 2025-11-25 |  | M |  |  | 2796 | <sup>(1)</sup> | 2028-07-29 | Common Stock | 2796 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $0.615 | 2025-11-25 |  | M |  |  | 94268 | <sup>(1)</sup> | 2028-10-17 | Common Stock | 94268 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $6.364 | 2025-11-25 |  | M |  |  | 43064 | <sup>(1)</sup> | 2029-12-12 | Common Stock | 43064 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $21.09 | 2025-11-25 |  | M |  |  | 4284 | <sup>(1)</sup> | 2029-12-12 | Common Stock | 4284 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $28.35 | 2025-11-25 |  | M |  |  | 3527 | <sup>(1)</sup> | 2030-12-07 | Common Stock | 3527 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $21.1 | 2025-11-25 |  | M |  |  | 4739 | <sup>(1)</sup> | 2031-12-07 | Common Stock | 4739 | $0 | 0 | D |  |

---

### Footnotes:

(1) The options are vested and currently exercisable.

**Signature:** /s/ Jonathan Young, Attorney-in-Fact  
**Date:** 2025-11-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**